Prolonged abstinence at longest · smokers with COPD
1 finding from 1 review
Point prevalence abstinence at longest · smokers with COPD
1 finding from 1 review
Overall survival (3 years) · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
It is very uncertain whether combination chemotherapy changes overall survival (3 years) compared with single‐agent chemotherapy (very low certainty).
1 finding from 1 review
Disease-free survival · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
It is very uncertain whether combination chemotherapy changes disease‐free survival (3 years) compared with single‐agent chemotherapy (very low certainty).
1 finding from 1 review
Complete response rate after preoperative chemoradiation (ypCR) · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy leads to higher complete response rate after preoperative chemoradiation (ypCR) compared with single‐agent chemotherapy (high certainty).
1 finding from 1 review
Toxicity ‐ early adverse events G3/4 · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy probably leads to higher toxicity ‐ early adverse events G3/4 compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Metastases intra‐abdominal · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy showed no clear difference in metastases intra‐abdominal compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Radiotherapy compliance · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy probably leads to lower radiotherapy compliance compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Chemotherapy compliance · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy leads to lower chemotherapy compliance compared with single‐agent chemotherapy (high certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations may leads to lower overall survival compared with 5‐FU/anthracycline combinations (without cisplatin) (low certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations probably leads to lower overall survival compared with 5‐FU/cisplatin combinations (without anthracyclines) (moderate certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations may leads to higher tumour response compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
1 finding from 1 review
Time to progression · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations may leads to lower time to progression compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in mortality (all‐cause) compared with tiotropium (moderate certainty).
1 finding from 1 review
Hospital admissions · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in hospital admission (all causes) compared with tiotropium (low certainty).
1 finding from 1 review
Exacerbations · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in exacerbation ‐ at 12‐month compared with tiotropium (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in serious adverse events (non‐fatal) compared with tiotropium (low certainty).
1 finding from 1 review
Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 pre‐dose ‐ FEV1 1 year · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate